Agefocus
Cognitive & Neuroprotection

NAD+

Cellular energy and cognitive function

Subcutaneous Injection Oral
Cellular energy restoration DNA repair enhancement Cognitive function support Anti-aging at cellular level Sirtuin activation

Overview

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in every living cell. It is essential for energy metabolism, DNA repair, and cellular signaling. NAD+ levels decline significantly with age, contributing to age-related diseases.

Mechanism of Action

Essential cofactor for sirtuins (SIRT1-7) → activates PARPs for DNA repair → required for mitochondrial electron transport → regulates circadian rhythm → modulates inflammatory pathways via CD38.

Benefits

  • Cellular energy restoration
  • DNA repair enhancement
  • Cognitive function support
  • Anti-aging at cellular level
  • Sirtuin activation
  • Improved mitochondrial function

Dosing Protocol

Typical Dose250–750 mg IV or 250–1000 mg oral (NMN/NR precursors)
FrequencyIV: 1–2x/month; Oral precursors: daily
Cycle LengthOngoing supplementation

Half-Life

~1–4 hours (IV); precursors vary

Duration of pharmacological activity after administration.

Side Effects

  • Flushing (IV)
  • Nausea
  • Headache
  • Chest tightness (rapid IV)
  • GI discomfort (oral)

Stacking Recommendations

EpithalonMOTS-cSemax5-Amino-1MQ

Storage & Reconstitution

IV solutions: use immediately. NMN/NR supplements: cool, dry place. Some products require refrigeration.

Research Notes

David Sinclair's research has popularized NAD+ supplementation. Multiple clinical trials ongoing for various age-related conditions. NMN and NR are the most common precursors. Decline begins around age 40.

Medical Disclaimer

This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Peptide therapy should only be initiated under the supervision of a qualified healthcare provider. Individual results may vary. Always consult with your physician before starting any new therapy. Regulatory status varies by jurisdiction.